Armored CAR-Ts? Memorial Sloan Kettering engineers CAR-T loaded with checkpoint inhibitors
Scientists at Memorial Sloan Kettering have engineered a hybrid cancer therapy that might just bring two of hottest areas of oncology science together in one package: CAR-T and checkpoint inhibitors.
That’s the hope of a team of MSK researchers working in the labs of Renier Brentjens, a renowned physician-scientist in New York City. They just published a paper in Nature — authored by Sarwish Rafiq, Oladapo Yeku, and Hollie Jackson — outlining their success in animal models.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.